29 August, 2017 by The TZ Newswire Staff Comments Off on UN Security Council condemns ‘outrageous’ North Korea missile launch
UN Security Council condemns ‘outrageous’ North Korea missile launch
The United Nations Security Council condemned North Korea’s firing of a ballistic missile over Japan on Tuesday as an “outrageous” threat.
29 August, 2017 by The TZ Newswire Staff Comments Off on Goldman is going to explain its trading strategy after investor pressure
Goldman is going to explain its trading strategy after investor pressure
The move comes after large investors expressed frustration over explanations for its core bond-trading unit’s troubles.
29 August, 2017 by The TZ Newswire Staff Comments Off on Residents told to evacuate on risk of explosion at Texas chemical plant
Residents told to evacuate on risk of explosion at Texas chemical plant
All residents within 1.5 miles of a Texas chemical plant were told to evacuate because of the risk of an explosion.
29 August, 2017 by The TZ Newswire Staff Comments Off on Goldman Sachs to break with precedent, discuss trading strategy
Goldman Sachs to break with precedent, discuss trading strategy
Reuters report on bond trading at Goldman Sachs, citing people familiar with the matter
– GS will detail plans to turn around performance at its core bond-trading unit next month
29 August, 2017 by The TZ Newswire Staff Comments Off on Debt Ceiling Part II
Debt Ceiling Part II
By David Kotok – Any time US Treasury balances are below $100 billion, don’t pay the federal legislature or their staff. Will this solution become law? No. They will never vote to discipline themselves.
29 August, 2017 by The TZ Newswire Staff Comments Off on Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today
Why Abeona Therapeutics Inc. (and Maybe Sangamo Therapeutics, Inc.) Jumped Higher Today
Shares of Abeona Therapeutics (NASDAQ: ABEO) jumped 18.4% on Tuesday, while shares of Sangamo Therapeutics (NASDAQ: SGMO) ended up 11.3%. The former is clearly because Abeona received a “breakthrough therapy” (BT) designation from the U.S. Food and Drug Administration for its EB-101 gene therapy program, for patients with recessive dystrophic epidermolysis bullosa. Sangamo is developing gene therapies of its own, albeit for different diseases, so it may be riding on Abeona’s coattails.